EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets
EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets
Under the terms of the License Agreement, AstraZeneca will grant Conduit an exclusive license to both AZD1656 and AZD5658 for all human indications, as well as an exclusive license to AZD5904 for use in Idiopathic Male Infertility.On Thursday, Conduit Pharmaceuticals Inc. (NASDAQ:CDT) entered into an agreement with AstraZeneca Plc (NASDAQ:AZN) to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators and AZD5904, a myeloperoxidase inhibitor (MPO).
週四，Conduit Pharmaceuticals Inc.（納斯達克股票代碼：CDT）與AstraZeneca Plc（納斯達克股票代碼：AZN）簽訂了協議，獨家授權開發Hk-4葡萄糖激酶活化劑AZD1656和AZD5658以及肌性過氧化物酶抑制劑（MPO）AZD5904的權利。
AstraZeneca had progressed AZD1656 and AZD5904 through Phase 1 clinical trials.
AstraZeneca已將AZD1656和AZD5904推進至第一階段臨床試驗。
Conduit initially intends to conduct Phase 2 clinical trials on candidates AZD1656 and AZD5658 in 2024 for applications in autoimmune disorders.
Conduit最初計劃在2024年對候選藥物AZD1656和AZD5658進行第2期臨床試驗，以用於自身免疫性疾病。
Under the terms of the License Agreement, AstraZeneca will grant Conduit an exclusive license to both AZD1656 and AZD5658 for all human indications, as well as an exclusive license to AZD5904 for use in Idiopathic Male Infertility.
根據許可協議的條款，AstraZeneca將授予Conduit AZD1656和AZD5658在所有人類適應症下的獨家許可證，以及對AZD5904的獨家授權，用於特發性男性不育症。
As part of the License Agreement, AstraZeneca will receive Conduit shares, and Conduit will also pay AstraZeneca a share of sublicense revenues, including upfront payments, milestones, and royalties received from future partners.
作爲許可協議的一部分，AstraZeneca將獲得Conduit的股份，Conduit還將向AstraZeneca支付特許轉讓收入的份額，包括未來合作伙伴支付的一次性付款、里程碑和版稅。
AstraZeneca will share pre-clinical and clinical data on the assets and supply Conduit with certain quantities of AZD1656, AZD5904, and AZD5658 from its inventory.
AstraZeneca將共享資產的臨床前和臨床數據，並向Conduit提供其庫存中特定數量的AZD1656、AZD5904和AZD5658。
The License Agreement also includes provisions for transferring know-how related to AZD1656, AZD5658, and AZD5904 from AstraZeneca to Conduit.
許可協議還包括將與AZD1656、AZD5658和AZD5904有關的技術知識從AstraZeneca轉讓給Conduit的條款。
AstraZeneca has been granted a right of first negotiation to develop, manufacture, and commercialize the licensed compounds if Conduit seeks to assign, license, or grant such rights to a third party.
如果Conduit尋求向第三方分配、許可或授予這些權利，AstraZeneca已獲得首要談判權，以開發、製造和商業化許可化合物。
Conduit departs from the traditional business model of shepherding assets through an entire commercial lifecycle by acquiring assets that have already undergone pre-clinical and clinical testing.
Conduit不按照整個商業生命週期引導資產的傳統業務模式，而是通過收購已經經歷過臨床前和臨床測試的資產來加速這些資產通過第二期試驗，並在成功時通過第三方許可機會尋求退出。
The company works towards accelerating the assets through Phase 2 trials and, if successful, intends to seek exits through third-party license opportunities.
上個月，Conduit Pharmaceuticals宣佈其主要資產Hk-4葡萄糖激酶激活劑已獲得組合物專利申請的IP Australia批准，針對一系列自身免疫性疾病的專利檢查取得了成功。
Last month, Conduit Pharmaceuticals announced the approval of a composition of matter patent application by IP Australia, achieving the successful examination of a patent on its lead asset, an HK-4 Glucokinase Activator, targeting a range of autoimmune diseases.
價格行動：上週四查看，AZN股票在盤前交易中下跌0.52%，報80.20美元。CDt股票在週三收盤時爲0.17美元。
Price Action: At last check Thursday, AZN stock was trading 0.52% lower at $80.20 during the premarket session. CDT stock closed at $0.17 on Wednesday.
儘管試驗結果不一，分析師仍認爲Exelixis處於拐點上。
- Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results.
- 儘管試驗結果不一，分析師仍認爲Exelixis處於拐點。
